ArticleWorld journal of clinical cases2025
Unexpected thrombocytopenia of a rare tamoxifen-induced complication in breast cancer therapy: A case report.
Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTamoxifen, a selective estrogen receptor modulator, is pivotal in managing hormone receptor-positive breast cancer. While its common side effects are well-documented, tamoxifen-induced thrombocytopenia is a rare, serious adverse event requiring drug discontinuation. CASE SUMMARY: We report a case of tamoxifen-induced thrombocytopenia in a 51-year-old premenopausal woman with breast cancer, occurring within 4 weeks of initiating adjuvant tamoxifen therapy. Platelet counts normalized after drug cessation, but thrombocytopenia recurred upon rechallenge, leading to permanent discontinuation.
conclusionThis case underscores the need for regular complete blood count monitoring in patients on tamoxifen to detect rare hematologic adverse events promptly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.